Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The barriers to a cure for multiple myeloma

Faith Davies • 26 Aug 2022
IMS 2022
Multiple Myeloma

Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, outlines the current challenges to achieving a cure for multiple myeloma. Prof. Davies first highlights our lack of knowledge about the biology of the disease, in particular in the context of novel immunotherapies, and further comments on the importance of treating patients earlier in the disease course and designing therapies for the frontline setting. Finally, Prof. Davies mentions some hurdles related to using novel therapies in clinical practice. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from Faith Davies

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
1:26
Identifying high-risk smoldering myeloma & minimizing treatment-related toxicity
Faith Davies • 26 Aug 2022
1:49
Factors to consider when sequencing therapies in myeloma
Faith Davies • 26 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals